NK Cell Therapy Market Summary

• The NK Cell Therapy Market Size in the 7MM is expected to grow with a significant CAGR during the study period (2020-2034).
• Key NK Cell Therapy Companies are MiNK Therapeutics, Indapta Therapeutics, ImmunityBio, Inc., Allife Medical Science and Technology, Nkarta, Base Therapeutics, GT Biopharma, Athenex, Ambicion, Biohaven Pharmaceuticals, Acepodia, Bright Path Biotherapeutics, Amgen, Innate Pharma, Nektar Therapeutics, SMT bio Co., Ltd., Alphageneron Pharmaceuticals, XNK Therapeutics, ImmunityBio, Cellid, Cantargia, Affimed Therapeutics, Takeda, Artiva Biotherapeutics, Sanofi, Dragonfly Therapeutics, INmune Bio, NKGen Biotech, Asclepius Technology Company Group, Glycostem Therapeutics (IPD Therapeutic), Wugen, Celularity, VERAXA, GamidaCell, Nkarta Therapeutics, Qihan Biotech, Century Therapeutics, Fate Therapeutics, Chimeric Therapeutics, Senti Biosciences, GICELL, Deverra Therapeutics, Medigen Biotechnology Corporation, GlaxoSmithKline, CytoImmune Therapeutics, Nuwacell Biotechnologies Co., Ltd., and others.

NK Cell Therapy Market Insight and Trends

• In January 2025:- New Approaches to Neuroblastoma Therapy Consortium- This Phase II study evaluates patient response to treatment with a combination of dinutuximab, temozolomide, irinotecan, and GM-CSF. It incorporates an advanced method to produce specially selected donated NK cells, which may be more effective than the patient's own NK cells. These donated NK cells, known as TGF-beta imprinted, might have enhanced tumor-killing capabilities, particularly against neuroblastoma, as they are exposed to TGF-beta during their preparation and growth.
• In October 2024, ImmunityBio announced the dosing of the first patients in an initial trial evaluating its CAR-NK cell therapy targeting CD-19 for the treatment of non-Hodgkin's lymphoma (NHL).
• In July 2024, Nkarta has received approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical trial evaluating its cell therapy candidate, NKX019, for the treatment of ANCA-associated vasculitis (AAV) and other autoimmune disorders.
• In April 2024, Ingenium Therapeutics announced that itsinvestigational therapy IGNK001 (Gengluecel) has been grantedOrphan Drug Designation by the US FDA for the treatment of AML.
• In May 2024, NKGen Biotech announced the publication of itsPhase I interim analysis results for SNK02 for advanced solidtumors. These results will be presented at the 2024 ASCO AnnualMeeting, held in Chicago from May 31 to June 4, 2024.

Request for Unlocking the Sample Page of the "NK Cell Therapy Treatment Market"

Key factors driving NK cell therapy market growth

Rising cancer incidence & clinical need

Increasing prevalence of hematologic and solid tumors that are refractory to conventional treatments is a major demand driver for NK-based immunotherapies. Clinical interest in NK cells as a complementary or alternative option to CAR-T and checkpoint inhibitors is expanding the addressable market.

Expansion of clinical trials and pipeline activity

A growing number of early- and late-stage trials (including CAR-NK programs) is accelerating validation, investor interest, and near-term commercialization prospects. More trials → stronger clinical evidence → faster adoption.

Technological advances

Improvements in gene-editing, CAR constructs for NK cells, allogeneic/off-the-shelf platforms, expansion protocols, and cryopreservation are reducing technical barriers and improving product consistency and scalability.

Investment, partnerships & M&A activity

Venture funding, pharma-biotech collaborations, and service-provider investments in CDMOs and cell-therapy manufacturing capacity are unlocking commercialization capability and lowering time-to-market

Regulatory clarity & orphan / expedited pathways

When regulators grant expedited designations or clearer guidance for cell therapies, developer risk falls and commercial timelines shorten, boosting market growth potential. (Seen across cell therapy segments.)

DelveInsight's "NK Cell Therapy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the NK Cell Therapy, historical and forecasted epidemiology as well as the NK Cells therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The NK Cell Therapy Treatment Market Report provides current treatment practices, emerging drugs, NK Cell Therapy market share of the individual therapies, current and forecasted NK Cell Therapy market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current NK Cell Therapy treatment market practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

NK Cell Therapy Disease Understanding

Natural Killer (NK) cell therapy is an emerging class of immunotherapy that leverages the innate immune system’s rapid, non–antigen-specific ability to recognize and destroy malignant or virally infected cells. NK cells function independently of prior sensitization, making them fundamentally different from T-cell–based therapies.

Mechanism of Action

NK cells identify target cells through a balance of activating and inhibitory receptors. Tumor cells often lose MHC class I molecules, reducing inhibitory signals and making them prime targets for NK-mediated cytotoxicity.

NK Cell Therapy Diagnosis

Diagnosis for NK-cell targeted treatment typically involves identifying underlying cancers or viral infections, assessing immune status, evaluating NK cell count and functional activity, and using biomarkers such as ligands for NK-activating receptors. Imaging, flow cytometry, and molecular profiling help determine disease burden and guide patient selection for NK-based clinical trials and therapies.

NK Cell Therapy Treatment

It covers the details of conventional and current medical therapies available in the NK Cell Therapy market for the treatment of the condition. It also provides NK Cell Therapy treatment algorithms and guidelines in the United States, Europe, and Japan.

NK Cell Therapy Epidemiology 

The NK Cell Therapy epidemiology division provide insights about historical and current NK Cell Therapy patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The prevalence of NK cell therapy is increasing, offering promising advancements in treating cancer and immune disorders with innovative immunotherapies.

Key Findings from NK Cell Therapy Epidemiological Analysis Report

The disease epidemiology covered in the report provides historical as well as forecasted NK Cell Therapy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

• The SEER database estimates that approximately 35,730 individuals (19,860 men and 15,870 women) were diagnosed with multiple myeloma in the United States in 2023, representing about 1.8% of all new cancer cases nationwide.
• Acute Myeloid Leukemia is among the most common types of leukemia in adults, though it remains relatively rare, comprising about 1% of all cancer cases. AML is slightly more prevalent in men than in women, but the average lifetime risk of developing AML for both genders is approximately 0.5%. According to DelveInsight's analysis, there were an estimated 30,000 new cases of multiple myeloma in the United States in 2023, with numbers projected to rise during the forecast period.
• The American Cancer Society's 2024 projections indicate that approximately 20,800 new cases of acute myeloid leukemia are anticipated in the United States, with the majority occurring in adults.

Country Wise- NK Cell Therapy Epidemiology

The epidemiology segment also provides the NK Cell Therapy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

NK Cell Therapy Drugs Analysis

The drug chapter segment of the NK Cell Therapy treatment market report encloses the detailed analysis of NK Cell Therapy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the NK Cell Therapy clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest NK Cell Therapy news and press releases. The cell therapy market is experiencing significant growth, driven by advancements in regenerative medicine, immunotherapy, and increasing clinical adoption worldwide.

NK Cell Therapy Marketed Drugs

The NK Cell Therapy therapeutics market report provides the details of the marketed product available for NK Cell Therapy treatment.

NK Cell Therapy Emerging Drugs

The NK Cell Therapy therapeutics market report provides the details of the emerging therapies under the late and mid-stage of development for NK Cell Therapy treatment.

• AlloNK: Artiva Biotherapeutics

AlloNK (also known as AB-101) is a cryopreserved, allogeneic NK (NK) cell therapy candidate that is not genetically modified. It is designed to enhance the effectiveness of B-cell-targeting monoclonal antibodies, promoting B-cell depletion. Developed as an off-the-shelf therapy, AlloNK is intended for use in combination with monoclonal antibodies and can be administered in community healthcare settings. Currently, a Phase I/II clinical trial is evaluating the combination of AlloNK and rituximab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

• oNKord: Glycostem

Glycostem develops innovative treatment options for hematological conditions and solid tumors through its first-generation NK cell-based immunotherapy, oNKord. This therapy received orphan drug designation for acute myeloid leukemia (AML) from the EMA in 2014 and the FDA in 2016. Currently, oNKord is undergoing evaluation in a Phase I/IIa clinical trial for the treatment of acute myeloid leukemia.

• FT522: Fate Therapeutics

FT522 is an innovative off-the-shelf CAR NK cell therapy designed to target and eliminate multiple pathogenic cell types, addressing systemic autoimmunity without the need for patient lympho-conditioning. Currently, it is being assessed in a Phase I clinical trial for relapsed/refractory B-cell lymphoma. Additionally, the company intends to broaden the clinical development of the FT522 program to include autoimmune diseases.

Stay ahead with key updates on NK Cell Therapy treatments. Access the 2025 pipeline report for exclusive insights!

NK Cell Therapy Market Outlook

The NK Cell Therapy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted NK Cell Therapy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a thorough detail of NK Cell Therapy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated NK Cell Therapy Market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

"According to DelveInsight, NK Cell Therapy Treatment Market in 7MM is expected to change in the study period 2020-2034"

Key Findings

This section includes a glimpse of the NK Cell Therapy therapeutics market in 7MM.

The United States NK Cell Therapy Market Outlook

This section provides the total NK Cell Therapy treatment market size and market size by therapies in the United States.

EU-5 Countries NK Cell Therapy Market Outlook

The total NK Cell Therapy treatment market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan NK Cell Therapy Market Outlook

The total NK Cell Therapy treatment market size and market size by therapies in Japan is also mentioned.

NK Cell Therapy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the NK Cell Therapy drugs market or expected to get launched in the market during the study period 2020-2034. The analysis covers NK Cell Therapy market uptake by drugs; patient uptake by therapies; and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

NK Cell Therapy Clinical Trial Analysis

The NK Cell Therapy market report provides insights into NK Cell Therapy clinical trials within Phase II, and Phase III stage. It also analyses NK Cell therapy Companies involved in developing targeted therapeutics.

NK Cell Therapy Pipeline Development Activities

The NK Cell Therapy therapeutics market report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for NK Cell Therapy emerging therapies.

Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL- Views on NK Cell Therapy

To keep up with current market trends, we take KOLs and SME's opinion working in NK Cell Therapy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or NK Cell Therapy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the NK Cell Therapy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the NK Cell Therapy Therapeutics Market Report

• The report covers the descriptive overview of NK Cell Therapy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the NK Cell Therapy epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for NK Cell Therapy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of NK Cell Therapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The NK Cell Therapy Therapeutics Market Report provides an edge while developing business strategies, by understanding trends shaping and driving the global NK Cell Therapy drugs market

NK Cell Therapy Therapeutics Market Report Highlights

• In the coming years, NK Cell Therapy drugs market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The NK Cell Therapy Companies and academics are working to assess challenges and seek opportunities that could influence NK Cell Therapy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major NK Cell Therapy Companies are involved in developing therapies for NK Cell Therapy. Launch of emerging therapies will significantly impact the NK Cell Therapy drugs market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for NK Cell Therapy
• Our in-depth analysis of the NK Cell Therapy pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

NK Cell Therapy Market Report Insights

• NK Cell Therapy Patient Population
• NK Cell Therapy Therapeutic Approaches
• NK Cell Therapy Pipeline Drugs Analysis
• NK Cell Therapy Market Size and Trends
• NK Cell Therapy Drugs Market Opportunities
• Impact of upcoming NK Cell Therapy Therapies

NK Cell Therapy Market Report Key Strengths

• 11 Years NK Cell Therapy Market Forecast
• 7MM Coverage
• NK Cell Therapy Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed NK Cell Therapy Drugs Market
• NK Cell Therapy Drugs Uptake

NK Cell Therapy Market Report Assessment

• Current NK Cell Therapy Treatment Market Practices
• NK Cell Therapy Unmet Needs
• NK Cell Therapy Pipeline Drugs Analysis Profiles
• NK Cell Therapy Drugs Market Attractiveness
• NK Cell Therapy Market Drivers
• NK Cell Therapy Market Barriers

Key Questions Answered In The NK Cell Therapy Market Report:

NK Cell Therapy Market Insights

• What was the NK Cell Therapy drugs market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the NK Cell Therapy treatment market size as well as market size by therapies across the 7MM during the study period (2020-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest NK Cell Therapy market size during the study period (2020-2034)?
• At what CAGR, the NK Cell Therapy drugs market is expected to grow in 7MM during the study period (2020-2034)?
• What would be the NK Cell Therapy market outlook across the 7MM during the study period (2020-2034)?
• What would be the NK Cell Therapy market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

NK Cell Therapy Epidemiology Insights

• What is the disease risk, burden and NK Cell Therapy Unmet Needs?
• What is the historical NK Cell Therapy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of NK Cell Therapy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to NK Cell Therapy?
• Out of all 7MM countries, which country would have the highest prevalent population of NK Cell Therapy during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current NK Cell Therapy Treatment Market Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the NK Cell Therapy treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of NK Cell Therapy in the USA, Europe, and Japan?
• What are the NK Cell Therapy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many NK Cell Therapy companies are developing therapies for the treatment of NK Cell Therapy?
• How many therapies are developed by each company for NK Cell Therapy treatment?
• How many are emerging therapies in mid-stage, and late stage of development for NK Cell Therapy treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the NK Cell Therapy therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for NK Cell Therapy and their status?
• What are the key designations that have been granted for the NK Cell Therapy emerging therapies?
• What are the global historical and forecasted NK Cell Therapy Drugs Market?

Reasons to Buy NK Cell Therapy Market Forecats Report

• The NK Cell Therapy market report will help in developing business strategies by understanding trends shaping and driving the NK Cell Therapy drugs market
• To understand the future market competition in the NK Cell Therapy drugs market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for NK Cell Therapy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming NK Cell Therapy Companies in the NK Cell Therapy drugs market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for NK Cell Therapy drugs market
• To understand the future market competition in the NK Cell Therapy drugs market

Stay Updated with us for Recent Articles:-

• NK Cell Therapy Infographic Market
• NK Cell Therapy Pipeline Infographic
• Latest DelveInsight Blogs